Literature DB >> 24900506

Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.

Fabio Del Bello1, Eleonora Diamanti1, Mario Giannella1, Valerio Mammoli1, Carla Marchioro2, Laura Mattioli3, Federica Titomanlio3, Alessandro Piergentili1, Wilma Quaglia1, Giovanni Benedetti4, Maurizio Varrone4, Maria Pigini1.   

Abstract

This study demonstrated that cyclomethyline (2) and the corresponding enantiomers (R)-(-)-2 and (S)-(+)-2, displaying α2C-adrenoreceptor (AR) agonism/α2A-AR antagonism, similarly to allyphenyline (1) and its enantiomers, significantly decreased the naloxone-precipitated withdrawal symptoms in mice at very low doses. It also highlighted that such positive effects on morphine dependence can even be improved by additional serotoninergic 5-HT1A receptor (5-HT1A-R) activation. Indeed, 1 or the single (S)-(+)-1, 2, or both its enantiomers, all behaving as α2C-AR agonists/α2A-AR antagonists/5-HT1A-R agonists, alone and at the same low dose, improved morphine withdrawal syndrome and exerted a potent antidepressant-like effect. Therefore, considering the elevated comorbidity between opiate abuse and depressed mood and the benefit of these multifunctional compounds to both disorders, it is possible that they prove more efficacious and less toxic than a cocktail of drugs in managing opioid addiction.

Entities:  

Keywords:  5-HT1A-R agonists; antidepressant-like effect; morphine withdrawal symptoms reduction; α2-adrenergic ligands

Year:  2012        PMID: 24900506      PMCID: PMC4025786          DOI: 10.1021/ml300064v

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

1.  Ligand modulation of [35S]GTPgammaS binding at human alpha(2A), alpha(2B) and alpha(2C) adrenoceptors.

Authors:  Valérie Audinot; Nelly Fabry; Jean-Paul Nicolas; Philippe Beauverger; Adrian Newman-Tancredi; Mark J Millan; Anne Try; Frédéric Bornancin; Emmanuel Canet; Jean A Boutin
Journal:  Cell Signal       Date:  2002-10       Impact factor: 4.315

2.  Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302.

Authors:  J Sallinen; I Höglund; M Engström; J Lehtimäki; R Virtanen; J Sirviö; S Wurster; J-M Savola; A Haapalinna
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

3.  Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine?

Authors:  Claudia Cardinaletti; Laura Mattioli; Francesca Ghelfi; Fabio Del Bello; Mario Giannella; Ariana Bruzzone; Hervé Paris; Marina Perfumi; Alessandro Piergentili; Wilma Quaglia; Maria Pigini
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

4.  Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine.

Authors:  Celia Goeldner; Pierre-Eric Lutz; Emmanuel Darcq; Thomas Halter; Daniel Clesse; Abdel-Mouttalib Ouagazzal; Brigitte L Kieffer
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

5.  Clonidine potentiates the effects of 5-HT1A, 5-HT1B and 5-HT2A/2C antagonists and 8-OH-DPAT in the mouse forced swimming test.

Authors:  J P Redrobe; M Bourin
Journal:  Eur Neuropsychopharmacol       Date:  1998-08       Impact factor: 4.600

6.  In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus.

Authors:  R Mongeau; P Blier; C de Montigny
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

Review 7.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

Review 8.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

9.  The involvement of alpha 2A-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice.

Authors:  Umit Kazim Ozdogan; Janne Lähdesmäki; Kristo Hakala; Mika Scheinin
Journal:  Eur J Pharmacol       Date:  2004-08-23       Impact factor: 4.432

10.  alpha(1A)- and alpha(1B)-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse.

Authors:  Van A Doze; Evelyn M Handel; Kelly A Jensen; Belle Darsie; Elizabeth J Luger; James R Haselton; Jeffery N Talbot; Boyd R Rorabaugh
Journal:  Brain Res       Date:  2009-06-18       Impact factor: 3.252

View more
  5 in total

1.  Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.

Authors:  Fabio Del Bello; Eleonora Diamanti; Mario Giannella; Valerio Mammoli; Laura Mattioli; Federica Titomanlio; Alessandro Piergentili; Wilma Quaglia; Marco Lanza; Chiara Sabatini; Gianfranco Caselli; Elena Poggesi; Maria Pigini
Journal:  ACS Med Chem Lett       Date:  2013-07-22       Impact factor: 4.345

2.  Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction.

Authors:  Maria Elena Giusepponi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Laura Mattioli; Alan Hudson; Eleonora Diamanti; Fabio Del Bello; Mario Giannella; Valerio Mammoli; Corinne Dalila Paoletti; Alessandro Piergentili; Maria Pigini; Wilma Quaglia
Journal:  ACS Med Chem Lett       Date:  2016-09-08       Impact factor: 4.345

3.  Dual Alpha2C/5HT1A Receptor Agonist Allyphenyline Induces Gastroprotection and Inhibits Fundic and Colonic Contractility.

Authors:  Zoltán S Zádori; Ágnes Fehér; Viktória E Tóth; Mahmoud Al-Khrasani; László Köles; Szabina Sipos; Fabio Del Bello; Maria Pigini; Klára Gyires
Journal:  Dig Dis Sci       Date:  2016-02-10       Impact factor: 3.199

4.  A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus.

Authors:  Valerio Mammoli; Alessandro Bonifazi; Diego Dal Ben; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Maria Pigini; Wilma Quaglia; Ajiroghene Thomas; Amy H Newman; Sergi Ferré; Marta Sanchez-Soto; Thomas M Keck; Fabio Del Bello
Journal:  ChemMedChem       Date:  2016-03-15       Impact factor: 3.466

5.  The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Fabio Del Bello; Mario Giannella; Alessandro Piergentili; Wilma Quaglia; Donatello Carrino; Alessandra Pacini; Carla Ghelardini
Journal:  Neurotherapeutics       Date:  2020-07       Impact factor: 6.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.